secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagonist Therapeutics, Inc (PTGX)
CIK:        0001377121
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002724
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagonist updates pipeline; icotrokinra NDA Jul '25, rusfertide NDA Dec '25; Phase 3 UC/CD initiated
--------------------------------------------------------------------------------

- Icotrokinra (oral IL-23R) NDA for psoriasis filed Jul '25; Phase 3 ICONIC-UC and ICONIC-CD initiated Q4 '25; superiority vs deucravacitinib achieved.
- Rusfertide (hepcidin mimetic) NDA for polycythemia vera submitted Dec 29 '25; Phase 3 VERIFY met primary endpoint, p<0.0001.
- PN-881 (oral IL-17) Phase 1 started Q4 '25; PN-477sc triple agonist Ph1 initiation mid-'26; PN-8047 oral hepcidin dev candidate nominated Q4 '25.
- Up to $630M milestones from J&J plus 6-10% royalties; $200M opt-out payment from Takeda for rusfertide plus additional milestones.
- Total potential sales milestones from icotrokinra and rusfertide up to $1.2B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1377121/000110465926002724/0001104659-26-002724-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1377121/000110465926002724/tm262863d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002724

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer